Every time you turn around, it seems there is another test of some kind that needs to be run, or interpreted, or repeated. The amount of testing that patients undergo during and after cancer treatment could easily put a cramming-for-finals college student to shame. Even though all of this testing is necessary, valuable, relatively simple, and regularly occurring, it's can also be stressful, confusing, and just downright mysterious. What do the results mean? Am I okay? Is that result bad? Good? What do we do with this information? How can I do better on this test next time? Is high good? Is positive bad? Does anything need to change because of these test results? Why do we run this test so frequently? Why can't we run this other test more often? (It's because of insurance, isn't it? Ugh. I knew it.) and so on.
Trying to keep track of what test is what, what it's for, what the results can and can't tell us, and how often you need to have it done can be a real brain jumbler. It may be helpful to organize the different tests you'll receive into one (or more) of four categories—based on how your doctor will likely use the test & test results to influence or inform various aspects of your care.
Four Categories of Cancer Tests by Purpose***
Some tests fall into more than one category, and these multitasking tests are the ones with which you will become most familiar. A CT scan fits both Category 1 and Category 3. A biopsy fits into Categories 1 and 2, and sometimes Category 3. A tumor marker test may fit Categories 1, 2, and 3. A Complete Blood Count (CBC) panel usually fits best into Category 4, and a ctDNA test fits Category 3, and can also fit Category 1. Routine bloodwork is most often a Category 4 test.
Simply knowing how your doctor intends to use the test results can put things into perspective and ease the mind a bit. If your doctor runs a Category 2 test, you likely don't need to hold your breath because it's being conducted to help determine which treatments may work best for you, and it's not measuring your cancer burden. And when you have blood drawn prior to a chemotherapy infusion, it's likely being used as a Category 4 test to make sure your body is in good enough shape to endure another infusion. Category 1 tests are nerve-racking at the beginning, but it's Category 3 tests that usually bring about the most palpable fear and anxiety because those are the ongoing cancer-detecting tests. ~sigh~
When your doctor orders a test, ask them how they plan to apply the results. You do not need to memorize their responses because one test can be used for different purposes at different times. Just ask them what they're using it for and make a note for this test, this time.
Are you ordering this test for diagnostic, prognostic, or staging purposes? Is it going to determine my eligibility for a specific therapy? Is it to look for or measure cancer? Are you ordering this bloodwork to get a snapshot of how my body is handling everything, or are you looking for something in particular?
***If you ask a doctor if they are giving you "a Category 2 or 3 test," they may look at you like you've sprouted horns and wings. The category numbers mean absolutely nothing to healthcare professionals because they were assigned (by me) indiscriminately for the purposes of the discussion on this page. It was easier to type "Category 1" instead of typing the full description repeatedly. Use the above paragraph as a model for how to inquire about the purpose of tests so your doctor doesn't mistake you for a Griffin. :)
The following two panels are the most commonly run blood-based lab tests for cancer patients in treatment and under surveillance. Your clinic, cancer center, or oncologist may choose some or all of these tests, and they may include others in routine testing that are not listed.
The frequency of these tests, and all others, is determined by the clinicians who order the lab tests. "Routine" may mean weekly, biweekly, monthly, quarterly, etc., and the frequency is dependent upon a number of factors like treatment type, treatment schedule, cancer type, cancer stage, etc.
Tumor Markers like PSA, CA19-9, CA125, or CEA, for example, may also be included in routine testing if your doctor feels they are applicable to your condition and care.
Complete Blood Count (CBC)
Blood Chemistry/General Chemistry/Complete Metabolic Panel
A cancer cell can release its DNA into the bloodstream following apoptosis (the natural process of a cell killing itself), necrosis (cell death due to external factors, like cancer treatments), or, less commonly, via secretion. When cell death occurs, the cell can burst open and its contents can spill into the blood, including the tumor's unique DNA. This is called ctDNA, or circulating tumor DNA.
ctDNA can be detected in the blood using specialized tests that are looking for MRD (minimal residual disease) using next-generation sequencing (NGS). Once ctDNA hits the bloodstream, it is only present and detectable for a matter of hours before the body flushes it out. Therefore, the presence of ctDNA in the bloodstream is quite time-sensitive and indicates that there are tumor cells actively spilling their contents into the blood.
There are a number of FDA-approved and/or commercially available ctDNA assays including:
*CDx stands for companion diagnostic, defined by the National Cancer Institute as "a test used to help match a patient to a specific drug or therapy. For example, a companion diagnostic test may identify whether a patient’s tumor has a specific gene change or biomarker that is targeted by the drug. This helps determine if the patient should receive the drug or not. "
MRD, or Minimal Residual Disease, is molecular evidence of remaining cancer found in the blood after treatment has been given. Essentially, it can tell us if we "got it all" or if there are microscopic cells or clusters of cells, too small to be identified using imaging like CT or PET scans, still active in the body. The "M" in MRD can sometimes stand for molecular or measurable, though minimal is the most common.
MRD tests may look for ctDNA, intact cancer cells, proteins, or other biomarkers in the test sample. These tests may inform diagnosis, prognosis, or therapy selection, and may be used assess therapy response and to monitor for early recurrence or progression in patients who are in remission or on maintenance therapy.
There are different types of MRD tests depending on your cancer type and whether you have solid or liquid (blood-based) tumors. Some tests require a blood sample, some require a bone marrow sample (myeloma), and others may require both blood and tumor tissue samples. Talk to your doctor about testing for minimal residual disease, if it's appropriate for you, and how it may inform and impact your cancer care.
Here's a short video from the Cancer Support Community on MRD.
Here's a short video from the Leukemia & Lymphoma Society on MRD testing for blood cancers.
A tumor-informed, or tumor-dependent, ctDNA test is one that requires a sample of your blood and tumor tissue. The testing company will create a molecular genomic profile of your tumor from a tumor tissue sample (from biopsy or surgery) and will then look for those specific molecular characteristics in your blood. There may be 5, 15, or more specific characteristics that a given test is trying to match up. Tumor-informed ctDNA tests are not designed to look for tumor DNA that is different from that of your primary (sampled) tumor, and cannot, therefore, identify new or genetically different secondary cancers. It is looking specifically for the DNA signature of your primary (or sampled) tumor. This type of test cannot tell us the location of those active tumor cells though. It can only tell us that they are present somewhere in the body. Until the tumor is large enough to be detected using imaging, it is not currently possible to know the location using a test like this.
If ctDNA is identified in your blood following treatment, it could indicate recurrence or relapse.
See the infographic below for a visual explanation of tumor-informed ctDNA detection.
Tumor-agnostic, or tumor-independent or tumor-uninformed, ctDNA tests do not require a tumor sample for matching tumor DNA in the blood, but are instead looking in your blood for genetic characteristics commonly found in specific types of cancers. Each test has its own proprietary collection of molecular genetic tumor data for which it is searching. Given that this type of ctDNA test does not need a tissue sample, it is less invasive than a tumor-informed ctDNA test.
This type of ctDNA test could potentially identify new secondary tumors, but it cannot tell us the location of those tumors. Until the tumor is large enough to be detected using imaging, it is not currently possible to know the location in the body using a test like this.
Contact the manufacturer and your doctor to learn more about these tests, their results, and how the results can be used.
There are a number of oncologists who have said, "I really don't know what to do with this information."
There are a few scenarios that exist with some ctDNA tests for which treatment guidelines have not yet been established or clearly defined. The technology is new and its clinical applications are still being refined.
In using ctDNA tests to monitor for recurrence, for example, there is a bit of a limbo phase that can arise when cancer is detectable in the blood but undetectable on a scan. If a patient tests positive for ctDNA after treatment is complete and there is no evidence of disease (NED) on scans, oncologists do not yet have clear guidance on what to do next. Should they start the patient on chemotherapy? Should they watch & wait until the suspected recurrence is visible on a scan? Should they order a different imaging study? What's best for the patient? What is considered overtreatment in this case? Are they worrying the patient too early, before they can offer help? The information is not always actionable depending on the situation, though standard of care regarding ctDNA testing is already changing and becoming more clear with some cancer types. Clinical utility is another term to describe if a test is actionable in some way, or if it can it be used or applied to patient care in a clinical setting.
A cohort study published in JAMA in January 2024 compared the detection rates of targetable mutations using both tissue-based sampling and ctDNA. In their publication, they noted, "Used alone, ctDNA-based testing may produce false-negative results for low-shedding tumors as well as false-positive results from clonal hematopoiesis of indeterminate potential (CHIP). Due to the potential for false-negative results, NCCN lung cancer guidelines recommend reflex tissue-based sequencing if actionable variants are not identified in ctDNA results. Moreover, published guidelines elaborating standards for analytical performance characteristics of ctDNA have not been well established, in contrast to tissue-based testing. Despite these limitations, ctDNA testing is rapid, noninvasive, and suitable for detecting variants arising from molecular heterogeneity and clonal evolution of resistance mutations."
Learn more about the results of the cohort study here.
A liquid biopsy uses a blood sample, instead of tissue or solid tumor sample, to look for and analyze cancer cells or cancer DNA. The term liquid biopsy is often used interchangeably with ctDNA test, MRD test, or the brand name of the test being used.
cfDNA (cell-free DNA) are fragments of DNA that have leaked out of a cell and into the bloodstream following apoptosis, necrosis, or secretion. ctDNA is the specific cell-free DNA of a tumor circulating in the bloodstream.
ctDNA is a biomarker. Biomarkers are measurable biological substances in the body, like proteins or genes, that can provide information about a disease or condition, and may influence your diagnosis, prognosis, and treatment selection. Biomarkers are found in tissue and bodily fluids like blood or urine. Some biomarkers are specific to a cancer type, and others can be applied more broadly.
Biomarkers may:
Some common biomarkers in cancer are: genomic instability/deficient DNA mismatch repair (MSI-H/dMMR); tumor mutational burden (TMB); ctDNA; somatic mutation status of cancer-related genes including TP53, KRAS, BRCA1, BRCA2, EGFR, PTEN, and PD-L1; and tumor markers like PSA, CEA, CA-125, AFP, CA 19-9, and BCR-ABL.
Fun Fact: More commonly known biomarkers are blood pressure, pulse, and body temperature.
Contact the patient care division of the ctDNA testing company your doctor has chosen to learn more about their specific tests, how they work, what they can and can't tell us, and what the results mean. Your doctor will determine if the test is necessary/right for you, if the results are actionable and what, if anything, they recommend you do next.
For the majority of blood-based lab tests, there is a reference range, or "normal" range, associated with each test to guide clinicians in their interpretations of the results. Values outside of this range can either be high or low, and the clinical significance of the value is specific to each test and the lab that performed the analysis. Reference ranges can vary from lab to lab so be sure you are comparing your results to the reference ranges listed on your lab report. "Normal" ranges are based on averages, but what's normal for you may be slightly higher or lower than the reference range. You can establish what's typical for your body along with your doctor, likely over the course of several successive tests. Furthermore, when you are going through cancer treatment, your "normal" may shift while your body adjusts to, metabolizes, and reacts to the treatment.
Lab work values in the "normal" range do not always mean "healthy with no underlying concerns," and values outside of the "normal" range do not always indicate illness, disease, or dysfunction. Lab work tells us part of the story, but not always the whole story.
When assessing lab results, it can be challenging not to fixate on the value of a single routine test, or get derailed by several results listed in red text or inside of red boxes. Yikes! What does that mean?! A test result of 38 that jumps to 41 a month later, for example, may not be cause for concern. On the other hand, small rises or falls on other tests may be of more concern. Each test has different thresholds of acceptable variation. Too often, a patient or caregiver gets wound up and stressed about an out-of-range lab result but their doctor is nonchalant and unbothered by the same result. We need to get on the same page with our doctors so we know what means what.
Ask your doctor what's acceptable and worrisome to them in terms of out-of-range lab results for each routine test so you're not thrown for a loop every time you get lab results outside of the reference range. Some tests may only be worrisome if they are out-of-range on the high side, others if they are out-of-range on the low side, while others may signal concern if they are out-of-range on either side, low or high. Some tests may have more wiggle room for fluctuation, and other tests may require close attention to, what appear to be, mild/slight elevations or drops.
Not all lab tests have a low-normal-high reference range. Some tests require a result to be above X or below X to be considered "normal." For example, on Test D, a "normal" result is anything above 20, and on Test E, a "normal" result is anything below 4.5. Other tests may not have a reference range or specific value (number) associated with them, but instead are simply reported as positive or negative. Keep in mind that the word negative does not always have a bad/poor connotation in medicine and oncology, and positive does not always have a good connotation. You can be negative for cancer (great news!) or positive for cancer recurrence (not great). Talk to your doctor about how you can best understand what your lab test results mean.
For tests that have a reference range, you can ask your oncologist to use an upper limit of normal (ULN) or a lower limit of normal (LLN) multiple to guide your understanding of the severity or relevancy of abnormal results.
Here's an example: Let's say TEST A has a reference range of 50-100. We can find the limit multiple by dividing the result by the limit. If your result is high, you will use the top of the reference range, and if your test result is low, you will use the lower end of the range for your calculation. TEST RESULT / UPPER OR LOWER LIMIT = LIMIT MULTIPLE
Now that the math is figured out, we can use this information to communicate with doctors about an out-of-range result and whether or not it's concerning. You can ask your doctor something like, "I see that my liver enzyme ALT test came back high and is two times the upper limit of normal. Does that worry you? If not, at what point would you be worried? 4x ULN? 6x ULN?" You can then jot down their response and refer back to it after future blood draws. Dr. Grey is not concerned until TEST B is 5x the ULN or greater. Please note: This is specific to each and every test, and is also subjective. It can be different depending on the doctor you ask, their specialty, the relevancy of the test to their specialty, etc. If TEST C is high, you will also need to ask your doctor what multiple of the ULN or LLN is acceptable or worrisome on this test from their perspective. With a few conversations, you may be able to create a cheat sheet that summarizes your doctor's parameters of concern for each routine lab test, or for the routine tests that, for you, most often come back too high or too low.
Sample Lab Test Cheat Sheet
Dr. Grey says not to worry until...
Using multiples of ULN and LLN from your doctor may make it easier, clearer, or faster to assess whether or not your out-of-range lab test results require additional consideration or immediate attention. If your lab test results pop up in your patient portal at night, you can cross-reference your cheat sheet for peace of mind. If all of the out-of-range results are within acceptable multiples, as determined through conversations with your doctor, you can continue to enjoy your evening. If a result happens to fall outside of this "acceptable multiple window," you can send a message to your doctor through your portal or call the office the next morning for follow-up. You may save yourself some unnecessary stress and anxiety by gathering this information in advance of your next test.
Specificity and sensitivity are quantitative measures of a test's clinical performance, meaning how good is the test at doing what it's designed to do for patients?
These concepts can get a little fuzzy given the way they're often described, so we won't focus too much on all the details right now. Instead, we'll discuss how a test's sensitivity or specificity correlates with its results and what that means for you.
Where's My Unicorn Test?
If you're looking for a test, be it a scan, blood test, or other lab test, to have 100% specificity and 100% sensitivity, you're going to be disappointed because it's not a thing. This would be considered a unicorn and, even though researchers and test developers strive for 100+100 in theory, in practice it's not realistically achievable. As you can imagine, there is give-and-take when designing these tests and factors like cost, time, availability of resources, feasibility, safety, reliability, and accuracy all come into play. Each of these factors can have an impact on the test's sensitivity and specificity, usually in an inverse relationship to each other. If one goes up, the other goes down. You can see the tug-of-war that can arise when designing a test and trying to determine the avenue (100% specificity or 100% sensitivity) that ultimately provides the most benefit and least harm to patients. Since there are no perfect tests, we have to work with the ones we've got so let's take a look at these two measures of clinical performance: specificity and sensitivity.
Up first...
SPECIFICITY
How specific is that test? is another way of saying...
SENSITIVITY
How sensitive is that test? is another way of saying...
Another way to describe test results:
True positive- test is positive and patient does have cancer
True negative- test is negative and patient does not have cancer
False negative- test is negative but patient does have cancer
False positive- test is positive but patient does not have cancer
Please don't worry that every test result is inaccurate or misleading. These are the best tests we have and they are reliable MUCH more often than not. Plus, there are multiple ways to test for most things which means there are likely tests out there that can step in and double-check the work of the previous test.
When your doctor orders a test, ask them if it's more likely to produce a false positive (tells me I have it when I don't) or false negative (tells me I don't have it when I actually do). By knowing that information, you can shift your expectations as needed about the test results. If you're concerned about a result, you can ask your doctor how confident they are in the result, if you can retake it and/or if there is another test out there that could provide similar information.
We regularly review these resources to make sure that all links work correctly and are of value to our visitors. If you find a link that isn't working, please email coral@oncologyoffense.com. If you would like us to consider adding a resource to our list, please email us with details.
Understanding Your Lab Test Results (American Cancer Society)
Understanding Your Lab Test Results | American Cancer Society
Lab Tests Online Read over 400 expert-reviewed lab test guides to better understand what each test measures, how it's used, and when you might need a particular test, and more.
Learn More About Lab Tests - Testing.com
NCI- Common Tumor Markers
Tumor Markers in Common Use - NCI (cancer.gov)
Colorectal Cancer Biomarkers (Fight Colorectal Cancer)
Colorectal Cancer Biomarkers [2023 Patient Guide] | Fight CRC (fightcolorectalcancer.org)
An Oncologist Explains Routine Blood Tests Performed in Cancer Patients (CancerConnect)
Molecular Biomarkers in Cancer (Sarhadi, et al. Biomolecules 2022 Aug; 12(8): 1021.) Clinical applications of biomarkers are extensive. They can be used as tools for cancer risk assessment, screening and early detection of cancer, accurate diagnosis, patient prognosis, prediction of response to therapy, and cancer surveillance and monitoring response. Therefore, they can help to optimize making decisions in clinical practice.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331210/
The ASCP Patient Champions program focuses on teaching patients and caregivers about the laboratory so they can better understand their options and choose the treatments that work best for them. Receiving a serious diagnosis can be life-changing. Patients and their caregivers can help take control of their treatment and care options by learning everything they can about a diagnosis, which includes laboratory and pathology results.
https://www.ascp.org/content/patient-champion
Deciphering Your Lab Report (Testing.com)
https://www.testing.com/articles/how-to-read-your-laboratory-report/
Reference Ranges and What They Mean (Testing.com)
https://www.testing.com/articles/laboratory-test-reference-ranges/
American Society for Clinical Pathology
ASCP - American Society for Clinical Pathology
Cancer Screening: What Blood Tests Can (and Cannot) Tell You (Peter Attia MD)
https://peterattiamd.com/cancer-screening-what-blood-tests-can-tell-you/
Understanding MRD in Solid Tumors (residual disease after treatment) (BloodPAC)
Understanding MRD in Solid Tumors — BLOODPAC
FDA Approves Blood Tests That Can Help Guide Cancer Treatment (ctDNA testing) (NCI)(ctDNA=circulating tumor DNA- this article is from 2020 and additional ctDNA tests have been approved by the FDA since then)
FDA Approves Blood Tests That Can Help Guide Cancer Treatment - NCI
The Evolution of Liquid Biopsy in Cancer Care: Five experts discuss how blood-based platforms are helping inform clinical decision-making, their potential in early detection, and the challenges ahead. (ASCO, October 10, 2021)
https://ascopost.com/issues/october-10-2021/the-evolution-of-liquid-biopsy-in-cancer-care/
Regulatory Implications of ctDNA in immuno-oncology for solid tumors (Vellanki PJ, Ghosh S, Pathak A, et al. Journal for ImmunoTherapy of Cancer 2023;11:e005344. doi: 10.1136/jitc-2022-005344)
https://jitc.bmj.com/content/11/2/e005344
FLT3-ITD Measurable Residual Disease Monitoring in Acute Myeloid Leukemia Using Next-Generation Sequencing (Lee, Jong-Mi et al. Cancers vol. 14,24 6121. 12 Dec. 2022.)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776673/
Liquid Biopsy (Cleveland Clinic) A liquid biopsy is a blood test that detects cancerous tumors. As a tumor grows, pieces can break off and circulate in your bloodstream. A liquid biopsy can identify those pieces.
https://my.clevelandclinic.org/health/diagnostics/23992-liquid-biopsy
Liquid biopsies: the future of cancer early detection. (Connal, Siobhan et al. Journal of translational medicine vol. 21,1 118. 11 Feb. 2023, doi:10.1186/s12967-023-03960-8)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922467/
Signatera Test by Natera Signatera™ is a highly sensitive and personalized molecular residual disease assay (MRD) using circulating tumor DNA (ctDNA), custom designed for each patient to help identify relapse earlier than standard of care tools.
https://www.natera.com/oncology/signatera-advanced-cancer-detection/
FoundationOne®CDx and FoundationOne®Liquid CDx Foundation Medicine tests use comprehensive genomic profiling, also known as CGP, to find information in your tumor’s DNA that may help your doctor identify a personalized cancer treatment plan that is right for you.
https://www.startwithstepone.com/
NeoGenomics RaDaR® (Residual Disease and Recurrence) MRD Testing by InivataThe high-performance personalized minimal residual disease (MRD) and recurrence test with exceptional sensitivity and specificity, with a simple blood draw.
Guardant Complete is a range of liquid and tissue tests for patients with early-stage and advanced-stage cancer. The results of each test enable your doctor to: monitor your
cancer status, make treatment decisions, and see if your treatment is working or not.
https://www.guardantcomplete.com/patients
Caris Life Sciences Molecular Profiling Test Our advanced tumor profiling approach analyzes your DNA, RNA and proteins to better understand your cancer at the molecular level. This information can help your oncologist figure out where the error in the cells may be occurring and what treatments may be the most effective.
https://www.carislifesciences.com/patients/
NeoGenomics InVisionFirst®-Lung is a liquid biopsy (blood) test used to help you and your care team determine the best treatment for patients with advanced non-small cell lung cancer (NSCLC). This is known as precision medicine. The results can be available in as little as 7 days.
https://neogenomics.com/invisionfirstr-lung
GRAIL Galleri Test is the first-of-its-kind multi-cancer early detection test that looks for a signal shared by 50+ types of cancer with a single blood test. The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. It is intended to be used in addition to and not replace other cancer screening tests your healthcare provider recommends.
Invitae Personalized Cancer Monitoring™ Understanding your genes can help guide you and your doctor to the most effective treatments, bringing you one step closer to beating cancer and then staying healthy in the long term. The Baseline Test compares germline with tumor exome sequencing to develop a customized patient and tumor-specific molecular signature for detecting circulating tumor DNA in plasma. Following a Baseline Test, the Monitoring test can assess the presence or absence of a patient’s tumor-specific molecular signature.
https://www.invitae.com/us/cancer
clonoSEQ by Adaptive measures minimal residual disease (MRD). This helps uncover how much, if any, cancer remains in your body during and after treatment. For patients with multiple myeloma, chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), and diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma (NHL).
https://www.clonoseq.com/patients/
Haystack Oncology MRD Test (acquired by Quest Diagnostics) is a tumor-informed ctDNA test that is specifically designed for post-surgical MRD applications. It uses the next generation of circulating tumor DNA (ctDNA) detection technology to see through the noise and uncover residual, recurrent, and resistant disease earlier than any other minimal residual disease (MRD) test. Quest expects to adapt the MRD test developed at Haystack as the basis for new clinical lab services available beginning in 2024. Development efforts will focus initially on MRD tests for colorectal, breast and lung cancers.
Copyright © 2024 Oncology Offense - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.